857283-89-7 Usage
Description
3-PYRROLIDIN-1-YLBENZALDEHYDE is an organic compound that features a pyrrolidine ring attached to a benzene ring with an aldehyde group. This unique structure endows it with specific chemical properties that make it a versatile building block in various chemical reactions and applications.
Uses
Used in Pharmaceutical Industry:
3-PYRROLIDIN-1-YLBENZALDEHYDE is used as a reactant for the preparation of rhodanine derivatives, which serve as protease inhibitors. These inhibitors are crucial in combating bacterial toxins, playing a significant role in the development of new antimicrobial agents to address the growing concern of antibiotic resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 857283-89-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,7,2,8 and 3 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 857283-89:
(8*8)+(7*5)+(6*7)+(5*2)+(4*8)+(3*3)+(2*8)+(1*9)=217
217 % 10 = 7
So 857283-89-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H13NO/c13-9-10-4-3-5-11(8-10)12-6-1-2-7-12/h3-5,8-9H,1-2,6-7H2
857283-89-7Relevant articles and documents
INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY
-
, (2021/04/30)
The invention provides amides that inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
IMIDAZOTRIAZINONE COMPOUNDS
-
, (2013/10/08)
The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.